Low-dose chemotherapy of desmoid tumors.
Eight patients with desmoid tumors, symptomatic, and none a candidate for conservative surgery, were treated with weekly vinblastine, maximum dose 10 mg/week, and methotrexate, maximum dose 50 mg/week. Symptomatic relief was obtained in all patients. Using Eastern Cooperative Oncology Group (ECOG) criteria, two patients had a complete remission, one of which has lasted for 30 months, four patients have had partial remissions, one patient has had a mixed response, and one patient who has been treated for only 4 weeks, a minimal response. Toxicity has been minor and transient. Chemotherapy appears to be an acceptable alternative to radical surgery in selected patients with desmoid tumors.
Weiss
A J
AJ
Department of Medicine, Thomas Jefferson School of Medicine, Philadelphia, Pennsylvania.
Lackman
R D
RD
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001132:Arm; D005260:Female; D005350:Fibroma / Q000188:drug therapy*; D006801:Humans; D007866:Leg; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010386:Pelvic Neoplasms / Q000188:drug therapy; D012074:Remission Induction; D013899:Thoracic Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D008727:Methotrexate